Ligand Pharmaceuticals (LGND) Cash from Discontinued Operations (2010 - 2013)
Ligand Pharmaceuticals (LGND) reported Cash from Discontinued Operations of 642000.0 for Q1 2013, down 221.0% on a YoY basis from 530578.51 in Q1 2012, and down 83.43% sequentially from 350000.0 in Q4 2012.
Ligand Pharmaceuticals (LGND) Cash from Discontinued Operations (2010 - 2013) Analysis & Trends
Ligand Pharmaceuticals (LGND) has 3 years of Cash from Discontinued Operations data on file, last reported at 642000.0 in Q1 2013.
- For the quarter ending Q1 2013, Cash from Discontinued Operations fell 221.0% year-over-year to 642000.0; the trailing twelve-month figure through Dec 2013 stood at 642000.0 (up 28.67% YoY), and the FY2013 full-year result was 642000.0, up 28.67% from the prior year.
- Cash from Discontinued Operations retreated to 642000.0 in Q1 2013, from 350000.0 in the prior quarter.
- In the past five years, Cash from Discontinued Operations ranged from a high of 1000.0 in Q3 2010 to a low of 642000.0 in Q1 2013.
- A 3-year average of 260833.33 and a median of 275000.0 in 2012 frame the typical range for Cash from Discontinued Operations.
- Peak annual rise in Cash from Discontinued Operations reached 221.0% in 2013, while the deepest fall reached 221.0% in 2013.
- Tracing LGND's Cash from Discontinued Operations over 3 years: stood at 22000.0 in 2010, then slumped by 1490.91% to 350000.0 in 2012, then slumped by 83.43% to 642000.0 in 2013.
- Business Quant data shows LGND's Cash from Discontinued Operations at 642000.0 in Q1 2013, 350000.0 in Q4 2012, and 350000.0 in Q3 2012.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Discontinued Operations (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,981.90 Bn | 66,981.62 Bn | - | - |
| 2 | Nanobiotix | 1,930.48 Bn | 1,930.42 Bn | - | - |
| 3 | Akari Therapeutics | 1,071.19 Bn | 1,071.19 Bn | - | - |
| 4 | BeOne Medicines | 468.55 Bn | 463.76 Bn | 1.35 Bn | - |
| 5 | Vertex Pharmaceuticals | 123.04 Bn | 115.79 Bn | 2.59 Bn | - |
| 6 | Regeneron Pharmaceuticals | 70.31 Bn | 61.56 Bn | 3.31 Bn | - |
| 7 | Belite Bio | 63.40 Bn | 63.40 Bn | - | - |
| 8 | Argenx Se | 55.78 Bn | 50.60 Bn | 1.41 Bn | - |
| 9 | Alnylam Pharmaceuticals | 37.67 Bn | 34.66 Bn | 959.66 Mn | - |
| 10 | Ligand Pharmaceuticals | 5.96 Bn | 5.18 Bn | 48.45 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2013 | -642,000.00 |
| Mar 31, 2013 | -642,000.00 |
| Dec 31, 2012 | -350,000.00 |
| Dec 31, 2012 | -350,000.00 |
| Sep 30, 2012 | -350,000.00 |
| Sep 30, 2012 | -350,000.00 |
| Mar 31, 2012 | -200,000.00 |
| Mar 31, 2012 | -200,000.00 |
| Dec 31, 2010 | -22,000.00 |
| Dec 31, 2010 | -22,000.00 |
| Sep 30, 2010 | -1,000.00 |
| Sep 30, 2010 | -1,000.00 |